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Abstract
The in vitro biosynthesis of metallothionein (MT) has
been investigated in RBC precursors from human cord
blood in order to support  the hypothesis for the
nucleated precursor origin of MT in human red blood
cells (RBC). Human RBC precursors are obtained by
(i) separating glycophorin A+ (gly A+) cells using a
magnetic cell sorting (MACS) technique and by (ii) ex
vivo expansion of precursors BFU-E (burst forming
unit-erythroid) on methylcellulose semi-solid culture
media from mononuclear cells of cord blood.
Biosynthesis of MT is detected at the protein level, by
immuno-histochemical staining using a mouse
monoclonal antibody (E9) in ex vivo expanded RBC
precursors obtained from BFU-E. Expression of MT is
also detected at the mRNA level by MT specific reverse
transcriptase polymerase chain reaction (RT-PCR)
both in ex vivo expanded precursors from BFU-E and
in MACS separated gly A+ cells. In addition, the
expression of the fetal form of MT, MT-0 (also known
as MT-1H) at the mRNA level in glycophorin A+ cells,
is also confirmed by cDNA sequencing. With these
observations, to our knowledge, MT biosynthesis in
human erythroid precursors is reported for the first time.
Moreover, the current findings of MT-0 expression at
the mRNA level in gly A+ RBC precursors of hCB has
added one more member in the list of cells/organs like
fetal liver, human monocytes, non-neoplastic tissues
of adenocarcinoma etc., in which the expression of the
human fetal form of MT, i.e. MT-0, has also been
reported.
Introduction
Metallothioneins (MT), small cysteine-rich metal-
scavenging proteins, bind group IB (copper, silver, gold)
and IIB (zinc, cadmium, mercury) metal ions with high
affinity [1]. Since its discovery [2], MT biosynthesis has
been reported in plants, animals and microorganisms.
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Metallothionein occurrence or biosynthesis in human
blood cells like lymphocytes [3], monocytes [4], platelets
[5], has also been reported. Metallothionein at the mRNA
level has been described in reticulocytes by Lambert et
al. [6], who also have speculated on the possible role of
MT in differentiation. However, the inability of
erythrocytes to perform protein biosynthesis has asserted
several speculations on the origin of MT therein.
Nucleated red blood cells (nRBC) or RBC precursors like
proerythroblasts have been suggested as a potential site
of MT biosynthesis and hence considered as the source
of MT in mature RBC [7]. Metallothionein originated in
organs like spleen is also suggested to be transferred to
RBC [8]. It has also been hypothesized that the source of
MT in murine RBC is the early bonemarrow precursors
[9]. This was later supported by Huber and Cousins [10]
who reported that MT concentrations in erythroid
progenitor cells are responsive to dietary Zn intake and
status. Extrapolation of this speculation, i.e. MT
biosynthesis in nRBC, from mouse to human, has led us
to attempt in vitro biosynthesis of MT directly in erythroid
precursors from human cord blood (hCB). Moreover, the
investigation on the origin of MT in human erythrocytes
with conclusive answers would give rise  to an additional
parameter to consider the proposed correlation between
the overall metal status and the respective metal bound
MT present in erythrocytes. As fetal cell populations are
present in cord blood, investigation for the expression of
the human fetal form of MT, MT-0 (also known as MT-
H) in the nRBC from hCB is also of our particular interest.
Materials and Methods
Separation of nonadherent mononuclear cells from human
cord blood
Human cord blood was collected in acid-citrate-dextrose
solution from umblical cords of full term newborns and was kept
at 4°C for not more than 12 hours before use. Mononuclear cells
(MNC) from hCB were separated by density gradient centrifugation
on lymphoprepTM (Nycomed AS, Oslo, Norway) according to
Bøyum [11]. After washing 3× with PBS, MNC were incubated to
remove plastic adherent cells at 37°C for 18-24 hours in RPMI
1640 containing 5% (v/v) fetal calf serum, 0.01% (v/v) gentamycin,
2mM glutamine (all from GibcoBRL, Life Technologies Ltd.
Paisley, Scotland), 1% (w/v) glucose (Sigma, St. Louis, MO, USA),
10-5 M 2-mercaptoethanol (Fluka, Neu-Ulm, Germany); non-
adherent MNC were recovered and washed not more than 3× with
PBS.
Ex vivo expansion or purification of nucleated precursors of
RBC
Nucleated precursors of RBC were obtained from these non-
adherent MNCs in two different ways: (i) by culturing nonadherent
MNC in semi-solid methylcellulose culture (MC) media
(MethoCultTM, StemCell Technologies, Vancouver, BC, Canada).
Briefly, non-adherent MNC were mixed at a density of 104 cells/
mL in MC media supplemented with additional erythropoietin (3U/
mL) and interleukin-3 (5ng/mL); 1 mL/well of this cell suspension
was incubated in 24 wells tissue culture plates; ex vivo expansion
of erythroid precursors was carried out at 37°C in high humidity
with 5% CO2 and normal atmospheric O2; BFU-E colonies were
picked up under the microscope at day 12; the purity of the erythroid
precursors was checked by May-Grnwald-Giemsa staining; (ii)
by separating glycophorin A+ (gly A+) cells from non-adherent
MNCs following MACS (magnetic cell sorting) using glycophorin
A microbeads (reagents and equipments from Miltenyi Biotech,
Bergisch Gladbach, Germany) with a positive selection column
according to the instructions; purity of the separated gly A+ cells
was achieved by a second pass of positive selection of the separated
gly A+ cells using fresh reagents and another positive selection
column; purity was finally checked by flow cytometric analysis;
≥80% gly A+ cells were taken for further experiments.
In vitro Zn induction
Erythroid precursors obtained either by ex vivo expansion or
by MACS separation were cultured in liquid cell culture media for
the in vitro MT biosynthesis in RPMI 1640 (same as above only
with the exception of 15% (v/v) fetal calf serum) for 48 h at 37°C.
In vitro Zn induction for MT biosynthesis was carried out in similar
cultures of erythroid precursors with 100µM of Zn acetate and
hereafter referred as ‘induced culture’.
Immunohistostaining
Immunoperoxidase staining was performed with the cytospin
preparations of the erythroid precursor cells from control and Zn
induced cultures of BFU-E. Briefly, E9 (Dako, Carpinteria, CA,
USA) was used as the primary antibody, biotin conjugated rabbit
anti-mouse IgG was used as the secondary antibody, finally immune
reactivity was observed with peroxidase conjugated avidin-biotin
complex using 3-amino-9-ethyl-carbazole plus hydrogen peroxide
as substrate.
mRNA extraction, RT-PCR and cDNA sequencing
Poly(A) mRNA was extracted using MICRO-
POLY(A)PURETM (Ambion, Austin, TX, U.S.A.) both from control
(without additional Zn) and induced (with additional 100µM of
Zn) cell cultures of BFU-E colonies and of gly A+ cells; cDNA
was synthesized with equal amounts of extracted mRNA using the
GeneAmp RNA PCR Core kit (Perkin Elmer, Roche Molecular
System, Branchburg, NJ, U.S.A.) according to the manufacturer’s
instructions. Total MT and MT-0 specific PCR was performed
according to Pauwels et al. [4]; PCR and subsequent cloning for
sequencing was performed using the AdvanTAgeTM PCR Cloning
kit (Clontech, Palo Alto, CA, U.S.A.); plasmid isolation was
performed using High Pure Plasmid Isolation Kit (Roche
Diagnostics, Mannheim, Germany) and cDNA sequencing was
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performed using the DNA sequencing kit (T7 SequenaseTM version
2.0, Amersham Life Science, Buckinghamshire, UK) according to
the instructions.
Results and Discussion
Immunohistochemical staining for the presence of
MT expression reveals that MT biosynthesis is inducible
at the protein level after 48 hours upon Zn addition in the
cell culture of nRBC which was obtained by ex vivo
expansion of RBC progenitors (BFU-E) in semi-solid MC
culture media (Fig. 1). The ample presence (more than
Fig. 1. Immunohistochemical staining of
the cytospin preparation of nRBC with
mouse anti-MT (E9). Cells are obtained
from BFU-E colonies grown by culturing
nonadherent MNC from hCB on
methylcellulose semi-solid cell culture
media for 12 days and then cultured for
48 hours in liquid cell culture media with
or without additional 100µM of Zn. (a)
Cells from the control culture (left
untreated with additional 100 µM of Zn
supplement) were found negative for the
immune reactivity; (b) on the other hand,
cells obtained from the culture with
additional 100µM of Zn supplement at 0
hour of liquid cell culture phase were
found positive for the immune reactivity
(cytoplasm red in color).
90%) of positively stained nRBC shown in Fig. 1b
represent MT containing cells from Zn induced cultures
and are obviously the indication of the MT biosynthetic
capability of these cell populations. In contrast to the cells
from the induced culture, MT containing cells could not
be detected  in the control culture (Fig. 1a). Consequently
inducible expression of MT biosynthesis in the human
nRBC is concluded.
Both the consititutive and upregulated transcription
of MT mRNA are detected respectively in control and Zn
induced cultures of nRBC from BFU-E colonies and of
gly A+ cells. The electrophoretic pattern of equal volumes
Cell Physiol Biochem 2000;10:237-242
240
of amplified cDNA pools on agarose (2%) gel was
observed and photographed under ultra-violet illumination
after staining with ethidium bromide (Fig. 2). Total MT
specific amplified cDNA pools from a control culture of
nRBC from BFU-E colonies and of gly A+ cells are shown
in lane # 1 and lane # 3 respectively. Therefore, the
constitutive transcription of MT genes in human nRBC
obtained either by ex vivo expansion or by MACS
selection of gly A+ cells is demonstrated. The transcription
of MT mRNA from Zn induced cultures of nRBC from
BFU-E and of gly A+ cells is also observed and  presented
with total MT specific amplified cDNA pool in lane # 2
and lane # 4 from the respective cultures.
The expression of the fetal form of MT, i.e. MT-0,
attracts our special interest during this investigation while
cord blood was used as the source of nRBC. Therefore,
the mRNA expression of this isoform was determined.
The constitutive transcription of MT-0 mRNA is observed
in control cultures by the presence of an amplified cDNA
pool after total MT-0 specific RT-PCR and is represented
in lane # 5 (Fig. 2). The upregulated transcription of MT-
0 mRNA from Zn induced cultures is also observed and
presented by the MT-0 specific amplified cDNA pool in
Fig. 2. Electrophoretic profile of
total MT or MT-0 specific
amplified cDNA pools on 2%
agarose gel. Total MT specific
amplified cDNA pools from a
contol and an induced culture of
nRBC from BFU-E are
represented in lane # 1 and lane
# 2 respectively; similar cDNA
pools from a contol and an
induced culture of gly A+ cells
are represented in lane # 3 and
lane # 4 respectively; MT-0
specific cDNA pools from a
control and an induced culture of
gly A+ cells are represented in
lane # 5 and lane # 6 respectively;
mRNA was extracted from 48
hours old control and Zn induced
populations. M, 100 base pair
DNA size marker.
lane # 6 (Fig. 2). Furthermore, out of 10 clones of the
MT-0 specific amplified cDNA pool, 3 randomly selected
ones have been sequenced and the nucleotide sequence
of the human fetal form of MT (MT-0) was confirmed by
sequence similarity search using the basic BLAST [12].
Though not quantitative, yet the difference in band
intensity of the amplified total MT/MT-0 specific mRNA
extracted from the control and the Zn induced cultures
either of nRBC from BFU-E colonies or of gly A+ cells,
clearly represents upregulation of MT mRNA upon Zn
addition (Fig. 2).
Among all the speculations on the origin of MT in
human RBC, biosynthesis in nucleated precursor cells is
the most plausible one. The expression of MT mRNA in
control cultures of ex vivo expanded nRBC and of gly A+
cells and the increase of this expression with additional
Zn treatment in similar cultures of respective cell
populations from hCB demonstrates the MT biosynthetic
capability of human nucleated precursors of mature RBC.
With these observations, to our knowledge, constitutive
and upregulated transcription of MT mRNA in human
erythroid precursors is reported for the first time. The
presence of MT at the protein level is detected in the Zn
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induced cultures but not in the control cultures of earlier
forms of nRBC obtained from BFU-E colonies (Fig. 1).
This observation confers the absence of constitutive MT
expression at the protein level in nRBC from hCB.
Perhaps, it might be the aftermath of Zn starvation for 12
days in Zn free MethoCult medium. However, control of
the MT expression at the transcriptional level could also
be possible as at least weak signal of MT mRNA is
observed in the control cultures.
While the possibility exists of getting trace amounts
of mRNA from cells of other erythroid lineages which
are present <15% in the MACS separated gly A+ cells,
the isoform specific expression of MT-0, in such cell
population needs further clarification, which is currently
under investigation.
However, the kind of experimental proofs provided
in this communication does not exclude other possibilities
like, transfer of MT into the mature RBC, while there is
at least one report so far to our knowledge in which the
existence of an MT receptor in human astrocytes has been
described [13]. However, considering the possibility of
having both the exogenous and endogenous source of MT
in mature RBC, quite a number of emerging questions
including various functional aspects of MT, like heavy
metal homeostatis and detoxification, in nucleated
precursors of mature RBC are yet to be resolved.
The inverse relationship of cadmium-MT
concentrations between spleen, the major erythropoietic
organ, and RBC, suggested possible transfer of cadmium-
MT from spleen to RBC. In addition, MT induction by
CdCl2 in phenyl hydrazine treated anemic mice and prior
injection of erythropoietin in CdCl2 treated polyemia mice
also revealed the effect of erythropoiesis on MT induction
[8]. The present study is therefore, expected to provide
the commencement of the emerging  studies on the
correlation between erythropoiesis and MT biosynthesis.
Besides, the possibility of MT expression in nRBC in
circulation, perhaps in adults too, can also be assumed
from these findings. While Zn-MT in erythrocytes has
been suggested as an index for the Zn status [14, 15, 16],
it is important to know the origin of Zn-MT in erythrocytes
so that a proper correlation between Zn status and RBC
Zn-MT can be made.
The expression of MT-0 has been reported in Zn
induced human monocytes [4] and also in nonneoplastic
tissues from adenocarcinoma [17]. Therefore, the
detection of the MT-0 expression at the mRNA level in
erythroid precursors, a part of the whole blood cell
population from hCB, has once more extended the growing
list of the cells/organ(s) in which the expression of the
human fetal form of MT (MT-0) has been observed. The
possibility of the expression of other isoforms of MT in
cord blood nRBCs and even the overall expression of MT
in other cell types in hCB is still to be investigated.
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